Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

- PMLiVE

Innovative Trials named a finalist in the Inspiring Hertfordshire Awards

The patient recruitment organisation has been shortlisted in the Inspiring Hertfordshire awards

Innovative Trials

- PMLiVE

Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara

The biosimilar was seen to have no clinically meaningful differences to Stelara

- PMLiVE

BMS Foundation announces Robert A Winn Diversity in Clinical Trials Award Program

The $100m initiative was started in 2020 to increase diversity in clinical trials

Importance of Diversity in Pharma and Clinical Trials

No matter which sector you work in, diversity and inclusion are must-haves!

Impetus Digital

- PMLiVE

Amgen and UCB’s Evenity recommended by NICE for severe osteoporosis

In the UK, almost four million people are affected by osteoporosis, resulting in around 520,000 fragility fractures each year

Democratizing Brain Health with Digital Assessments

Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can...

Impetus Digital

- PMLiVE

Innovative Trials suspends services in Russia in response to Ukraine war

Kate Shaw, Founder & CEO of the leading patient recruitment organisation based in Letchworth (UK), on the current Russia-Ukraine situation.

Innovative Trials

- PMLiVE

Improving diversity in clinical trial patient recruitment

A key requirement for clinical trials is to understand the effect of potential treatments on the patient populations that will benefit most. Despite this, many studies find diverse patient recruitment...

Innovative Trials

- PMLiVE

Amgen shares new Otezla data at American Academy of Dermatology congress 2022

Around 125 million people worldwide have psoriasis, including an estimated 14 million people in Europe

- PMLiVE

FDA approves BMS’s Opdualag for metastatic or unresectable melanoma

The new, first-in-class fixed-dose dual immunotherapy combination treatment is administered as a single intravenous infusion

- PMLiVE

Sanofi reveals $330m collaboration with Blackstone Life Sciences

The partnership will focus on innovative treatment for multiple myeloma

Increasing patient randomisation rate by 200% for a Top 5 global pharma

Phase IIa Moderate to Severe Hidradenitis Suppurativa Case Study

Innovative Trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links